I feel very humbled to have been selected for TIME's 100 AI list for 2025! Thankful over the last 3 years to help to shape the @IsomorphicLabs drug design engine and to build the team leveraging it for drug discovery. #TIME100AI time.com/collections/time100…

The biosecurity landscape is rapidly evolving. To stay ahead of future outbreaks, we’re partnering with @IsomorphicLabs to outline our approach to bioresilience. Here’s how we’re deploying frontier AI to build proactive defenses for global health → goo.gle/4wKHXk2

Today we announced our $2.1 Billion funding. This is the catalyst that will bring us to a future of medicine with the power of AI. And we are just getting started, come join our mission.

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here: bit.ly/4v2OI03

“I think eventually, over the next 10 to 20 years, we could get to finding a solution to all disease…if we have a process that can find these needles in a haystack.” Isomorphic Labs Founder and CEO @DemisHassabis and the team took @FortuneMagazine’s @Agarfinks behind the scenes to see how it uses Iso’s drug design engine to sort through near-infinite chemical possibilities to find the right compound for a disease. The story captures the exciting momentum inside our doors right now, and our team's shared drive to shape the next chapter of medicine. fortune.com/article/demis-ha…

Join our Chief Scientific Officer, @MilesCcc, at @ELRIG_SCIENCE Drug Discovery 2025: Festival of Life Science in Liverpool, on 21 October at 14:00 BST, where he will explore how @IsomorphicLabs integrates its advanced structure prediction models with bespoke machine learning approaches to binding affinity and ADMET optimisation – unlocking chemical spaces traditional methods struggle to reach.

Join @maxjaderberg , our Chief AI Officer, and @MilesCcc, our Chief Scientific Officer, in a virtual fireside with @AndrewE_Dunn at the 2025 Endpoints AI Day on 14 October, from 11:00-11:40am EDT. Together, Max and Miles will delve into how AI and drug discovery come together in their work at Isomorphic Labs, and how our drug design engine enables us to operate across many different therapeutic areas and drug modalities.

Our Chief Medical Officer, Dr. Ben Wolf, will be joining @caseymross from 11:20 - 11:45am EDT on 16 October at the @STAT Summit to talk about why our mission to solve all disease inspired him to bring his 20 years of drug development experience to Isomorphic Labs.

Helping to improve human health is one of the most important uses of AI. Insightful discussion with @TomMackenzieTV on Bloomberg Tech Europe of our great progress @IsomorphicLabs designing new drug candidates for challenging targets. bloomberg.com/news/videos/20…

Our CEO @demishassabis, Chief AI Officer @maxjaderberg, and Head of Medicinal Drug Design @_rebecca_paul were featured on the latest episode of Bloomberg Tech Europe (@technology) to share how we're leveraging frontier AI in groundbreaking ways to reimagine drug discovery and advance human health Follow the link learn more about what Iso does and our progress towards solving all disease: bloomberg.com/news/videos/20…

The future of drug discovery isn't just about AI; it's about how AI empowers human experts. 🥼 Join @_rebecca_paul and @maxjaderberg from @IsomorphicLabs, as they share their insights with @fryrsquared on leveraging AI agents to explore vast molecular spaces. See their discussion ↓

Congratulations to our Chief Scientific Officer, @MilesCcc, who has been featured in the @TIME 100 AI list! Miles’ experience at the forefront of drug discovery is instrumental in our work developing a generalisable AI drug design engine and tackling targets that have long been considered too difficult to pursue. See the full list here: bit.ly/4fUtlr4 #TIME100AI

An energising visit from Nobel laureate & our Scientific Advisory Board member, Sir David MacMillan! He joined our Chief Scientific Officer, @MilesCcc, for a fireside chat on his career reshaping modern chemistry and his philosophy on pioneering new science.

We are thrilled to welcome Sarah Skerratt as our new Chief Research Officer! Her extensive medicinal chemistry and drug discovery expertise across multiple target classes will be instrumental in advancing our pipeline towards the clinic.

We're excited to welcome Dr. Ben Wolf, M.D., Ph.D., as our new Chief Medical Officer at Isomorphic Labs! Dr. Wolf brings nearly 20 years of biopharmaceutical experience to the team, and will be based in our new Cambridge, Massachusetts location as we advance therapeutic programs into the clinic using machine learning to transform drug design. Read more on our website: bit.ly/3G2p7QH

The ambition at @IsomorphicLabs is immense – they’re rethinking drug discovery from the ground up, using AI. 💊 Join Head of Medicinal Drug Design @_rebecca_paul & Chief AI Officer @maxjaderberg as they share the possibilities of AI in tackling disease with host @fryrsquared. Watch their conversation ↓ Timecodes: 00:00 Intro 02:11 AI & Disease 05:30 AI in Biology 06:51 Molecules and Proteins 12:05 AlphaFold 3 14:40 Demo 16:20 Human-AI collaboration 24:30 Drug Design Challenges 39:00 Beyond Animal Models 44:35 AI Drug Future 46:30 Outro

“The future of biology won’t be siloed—it will be collaborative, interdisciplinary, and deeply creative. Demis is helping us get there faster.” We’re thrilled to see our CEO, @demishassabis, recognised as one of TIME’s 100 Most Influential People in the world. In this feature, Demis is interviewed by Jennifer Doudna, a member of Isomorphic Labs’ Scientific Advisory Board. Read more at the link below. bit.ly/4cz5onP

Thrilled to announce @IsomorphicLabs has raised $600M to turbocharge our mission to one day solve all disease with the help of AI. I've long felt that improving human health is the most important thing we can do with AI & today marks a big step towards a new era of drug discovery.

Our expanded collaboration with @Novartis is a testament to the progress and potential of our work in reimagining drug discovery. Read more from @demishassabis in the full announcement here: isomorphiclabs.com/articles/… #AI #drugdiscovery #machinelearning

We are excited to announce the expansion of our collaboration with @Novartis, doubling the number of research programs just over a year after initiating our partnership. This expansion is testament to the great progress we’ve made together and further unlocks the potential to ultimately advance human health. Read more here: bit.ly/4i669WZ #AI #drugdiscovery #machinelearning